Open AccessCost-Effectiveness Analysis of Antithyroid Drug (Propylthiouracil) Compared to Radioactive Iodine for the Treatment of Graves’ Disease in Ethiopia
Author(s) -
Habtamu Solomon Mengistu,
Kidus Tesfaye Getahun,
Lake Alemayehu,
Sifrash Gezahign
Publication year - 2022
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s350984
Subject(s) - medicine , graves' disease , propylthiouracil , radioactive iodine , antithyroid drugs , pediatrics , antithyroid agent , cost effectiveness analysis , disease , drug , cost effectiveness , thyroid , pharmacology , risk analysis (engineering)
Graves' disease is an autoimmune disorder caused by stimulating antibodies. The peak incidence of Graves' disease occurs among patients aged 30 to 60 years. Radioactive iodine (RAI) and antithyroid drug (ATD) have been well-established therapies for the treatment of Graves' disease for several decades. However, there remain large variations in practice among physicians in the preferred modality and the method of administration.